1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Creative Life Science Co Ltd

Creative Life Science Co Ltd

TTPEX:7837
81.50
TWD
+0.50
(+0.62%)
2.10BMarket Cap
Creative Life Science Co Ltd
TPEX:7837
(Taipei Exchange)

Recent

price

81.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
TWD
- -
59.5
47.36
41.2
49.28
- -
Revenue per Share
- -
8.33
4.21
4.55
5.31
- -
Basic EPS, GAAP
- -
4.36
-3.72
8.58
3.68
- -
Free Cash Flow per Basic Share
- -
1.49
5.3
1.7
2.06
- -
Dividend per Share
10.88
16.57
13.08
27.77
32.37
32.77
Book Value per Share
10.77
16.35
12.8
23.47
28.26
28.76
Tangible Book Value per Share
22
13
14
21
22
23
Basic Weighted Avg Shares
- -
801
684
861
1,099
- -
Sales/Revenue/Turnover
- -
19.51
7.82
12.31
12.83
- -
Operating Margin (%)
- -
42
52
85
103
- -
Depreciation Expense
- -
112
61
95
118
- -
Net Income, GAAP
- -
20.27
19.55
19.53
11.75
- -
Effective Tax Rate (%)
- -
14
8.89
11.04
10.78
- -
Profit Margin (%)
148
207
118
320
230
195
Working Capital
29
76
222
315
289
261
LT Debt
243
370
293
622
725
748
Total Equity
- -
30.53
8.11
10.73
11.56
- -
Return on Invested Capital (%)
- -
20.87
9.4
12.51
11.77
- -
Return on Capital (%)
- -
36.52
18.34
20.81
17.61
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
46
63
61
LT Borrowings
120
140
127
LT Finance Leases
150
150
134
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
23
Market Capitalization
2,594
2,505
2,098

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
618
652
622
Cash, Cash Equivalents & STI
275
300
284
Accounts Receivable, Net
176
187
186
Inventories
113
117
101
Total Current Liabilities
381
422
427
Payables & Accruals
- -
- -
- -
ST Debt
46
63
61
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
16.58%
Free Cash Flow
- -
- -
-54.26%
Net Income, GAAP
- -
- -
24.57%
Sales/Revenue/Turnover
- -
- -
27.65%
Total Cash Common Dividend
- -
- -
28.95%

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
861
2025
- -
- -
1,099
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
4.55
2025
- -
- -
5.31
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.7
2025
- -
- -
2.06
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Creative Life Science Co., Ltd. is a Taiwan-based biotechnology and healthcare company engaged in the research, development, manufacturing, and commercialization of biomedical products, in vitro diagnostics, and functional health supplements. Founded in Taiwan and headquartered in Taipei, the company operates across specialized life science sectors, serving medical institutions, diagnostic laboratories, healthcare brand owners, and consumer wellness markets across Taiwan and the broader Asia-Pacific region. The company organizes its core business into several comprehensive product and service segments, comprising in vitro diagnostic (IVD) reagents, rapid test cassettes, and point-of-care testing systems for clinical diagnostics and infectious disease screening; specialized probiotic formulations, botanical wellness extracts, immune-support supplements, and functional nutritional health products; contract development and manufacturing organization (CDMO), original equipment manufacturing (OEM), and original design manufacturing (ODM) services for biopharmaceutical, cosmetic, and nutritional health brands; and life science laboratory supplies, including molecular biology test reagents, cell culture media, and biochemical analytical consumables. In recent corporate developments, Creative Life Science Co., Ltd. has advanced its capital and market presence through its public listing on the Emerging Stock Board of the Taipei Exchange under ticker TPEX:7837. Over the past two years, the company has upgraded and expanded its certified production infrastructure to scale its CDMO and diagnostic manufacturing capacity, established strategic co-development and distribution agreements with healthcare partners and regional research centers to introduce next-generation preventive diagnostics, and launched specialized lines of clinical-grade functional nutritional formulas. In addition, the company continues to broaden its international regulatory compliance and product registrations to support the geographic expansion of its diagnostic and wellness offerings into Southeast Asian and overseas markets.